Eurand Appoints Dr. Robert Becker as Chief Research Officer

MILAN, ITALY--(Marketwire - April 28, 2009) - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, today announced the appointment of Robert Becker, M.D., to the newly created position of Chief Research Officer of Eurand SpA, effective April 20, 2009. He is based at the Company’s Milan office and will oversee all research and formulation development activities worldwide.

“Robert is an important and welcome addition to Eurand’s global leadership team,” said Gearóid Faherty, Chairman and Chief Executive Officer. “His extensive experience in product development will help to fuel our continuing growth as a specialty pharmaceutical company focused on the gastroenterology market.”

Dr. Becker has nearly 25 years of pharmaceutical industry experience, most recently at Biogen Idec GmbH where, as Senior Director, Small Molecule Development International, he managed all CMC (chemistry, manufacturing and controls)-related small molecule activities. His background also includes a broad range of senior management positions in research and development at Lilly Research Laboratories and Boehringer Ingelheim.

He holds a Bachelor of Science degree and a Ph.D. in Physical Chemistry from the Technical University of Munich.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand’s website at www.eurand.com.

Forward-Looking Statement

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to, the future and status of the Company’s research, product development, product launches, enrollment and future plans for product development or activities. The words “potentially,” “anticipates,” “could,” “calls for” and similar expressions also identify forward-looking statements. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Investors are advised to refer to the Company’s Risk Factors set forth in its Annual Report on Form-20-F as filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements.